PMID- 38167134
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240106
IS  - 1710-1484 (Print)
IS  - 1710-1492 (Electronic)
IS  - 1710-1484 (Linking)
VI  - 20
IP  - 1
DP  - 2024 Jan 2
TI  - IL-1beta and iNOS can drive the asthmatic comorbidities and decrease of lung 
      function in perennial allergic rhinitis children.
PG  - 1
LID - 10.1186/s13223-023-00867-3 [doi]
LID - 1
AB  - BACKGROUND: Allergic asthma and rhinitis (AR) are closely linked, with a 
      significant proportion of AR patients developing asthma. Identification of the 
      early signs of comorbidity of AR and asthma can enable prompt treatment and 
      prevent asthma progression. OBJECTIVES AND METHODS: This study investigated the 
      role of interleukin-1beta (IL-1beta), a pro-inflammatory cytokine, and inducible nitric 
      oxide synthase (iNOS) in the comorbidity of AR and asthma and lung function in 
      Korean children with perennial AR (PAR). A cohort of 240 subjects (6 to 10 years 
      old) with PAR (PAR alone: 113 children, PAR and asthma: 127 children) was 
      analyzed for various biomarkers, including IL-1beta, iNOS, and 
      epithelial-mesenchymal transition (EMT) markers in serum. The blood levels of 
      eosinophils and immunoglobulin E (IgE) were examined. IL-1beta, CCL-24, E-cadherin, 
      and vimentin were measured by enzyme-linked immunosorbent assay (ELISA). 
      Epithelial iNOS was measured by the NOS kit. RESULTS: Elevated levels of IL-1beta, 
      iNOS, and vimentin in the serum were identified as significant indicators of the 
      likelihood of comorbidity of PAR and asthma in children. Furthermore, higher 
      concentrations of IL-1beta, iNOS, and vimentin have been linked to reduced lung 
      function in PAR children. Notably, IL-1beta expression shows a relationship with the 
      levels of E-cadherin, vimentin, and CCL-24. However, no correlation was found 
      between IL-1beta and iNOS expressions. CONCLUSIONS: This study suggests that IL-1beta 
      and iNOS can be biomarkers in the progression of PAR and asthma and decreased 
      lung function, suggesting potential targets for early intervention and treatment.
CI  - (c) 2023. The Author(s).
FAU - Han, Myung Woul
AU  - Han MW
AUID- ORCID: 0000-0001-8596-7699
AD  - Department of Otolaryngology, Ulsan University Hospital, University of Ulsan 
      College of Medicine, Ulsan, Republic of Korea. brightmoon@uuh.ulsan.kr.
FAU - Kim, Song Hee
AU  - Kim SH
AD  - Department of Otolaryngology, Ulsan University Hospital, University of Ulsan 
      College of Medicine, Ulsan, Republic of Korea.
FAU - Oh, Inbo
AU  - Oh I
AD  - Environmental Health Center, University of Ulsan College of Medicine, Ulsan, 
      Republic of Korea.
FAU - Kim, Yang Ho
AU  - Kim YH
AD  - Department of Occupational and Environmental Medicine, Ulsan University Hospital, 
      University of Ulsan College of Medicine, Ulsan, Republic of Korea.
FAU - Lee, Jiho
AU  - Lee J
AD  - Department of Occupational and Environmental Medicine, Ulsan University Hospital, 
      University of Ulsan College of Medicine, Ulsan, Republic of Korea. 
      leejh@uuh.ulsan.kr.
LA  - eng
GR  - Grant HC15C1335/Ministry of Foreign Affairs/
GR  - UUH 2020 06/Ulsan University Hospital/
GR  - NRF-2019R1I1A1A01059851/National Institute for International Education/
PT  - Journal Article
DEP - 20240102
PL  - England
TA  - Allergy Asthma Clin Immunol
JT  - Allergy, asthma, and clinical immunology : official journal of the Canadian 
      Society of Allergy and Clinical Immunology
JID - 101244313
PMC - PMC10763256
OTO - NOTNLM
OT  - Allergic rhinitis
OT  - Asthma
OT  - Comorbidity
OT  - E-cadherin
OT  - Epithelial-mesenchymal transition
OT  - IL-1beta
OT  - Vimentin
OT  - iNOS
COIS- The authors declare that they have no competing interests.
EDAT- 2024/01/04 01:18
MHDA- 2024/01/04 01:19
PMCR- 2024/01/02
CRDT- 2024/01/03 09:33
PHST- 2023/06/25 00:00 [received]
PHST- 2023/12/15 00:00 [accepted]
PHST- 2024/01/04 01:19 [medline]
PHST- 2024/01/04 01:18 [pubmed]
PHST- 2024/01/03 09:33 [entrez]
PHST- 2024/01/02 00:00 [pmc-release]
AID - 10.1186/s13223-023-00867-3 [pii]
AID - 867 [pii]
AID - 10.1186/s13223-023-00867-3 [doi]
PST - epublish
SO  - Allergy Asthma Clin Immunol. 2024 Jan 2;20(1):1. doi: 10.1186/s13223-023-00867-3.